In recent trading session, Abbvie Inc (NYSE:ABBV) saw 1.32 million shares changing hands at last check today with its beta currently measuring 0.48. Company’s recent per share price level of $182.48 trading at $0.8 or 0.44% at last check today assigns it a market valuation of $322.33B. That most recent trading price of ABBV’s stock is at a discount of -19.83% from its 52-week high price of $218.66 and is indicating a premium of 15.84% from its 52-week low price of $153.58.
For Abbvie Inc (ABBV), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.90. Splitting up the data highlights that, out of 27 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 7 suggested the stock as a Hold whereas 20 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of 3.18 in the current quarter.
Abbvie Inc (NYSE:ABBV) trade information
Upright in the green today for gaining 0.44%, in the last five days ABBV remained trading in the red while hitting it’s week-highest on Monday, 05/12/25 when the stock touched $182.48 price level, adding 5.3% to its value on the day. Abbvie Inc’s shares saw a change of 2.69% in year-to-date performance and have moved -1.15% in past 5-day. Abbvie Inc (NYSE:ABBV) showed a performance of 6.29% in past 30-days.
Wall Street analysts have assigned a consensus price target of 217.5 to the stock, which implies a rise of 16.1% to its recent value today. Analysts have been projecting 215 as a low price target for the stock while placing it at a high target of 220. It follows that stock’s current price would drop -17.82% in reaching the projected high whereas dropping to the targeted low would mean a loss of -17.82% for stock’s current value.
Abbvie Inc (ABBV) estimates and forecasts
This year revenue growth is estimated to rise 6.29% from the last financial year’s standing.
15 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 14.93B for the same. And 14 analysts are in estimates of company making revenue of 15.34B in the next quarter. Company posted 14.46B and 14.46B of sales in current and next quarters respectively a year earlier.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -14.67% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 20.77% while estimates for its earnings growth in next 5 years are of 15.17%.
Abbvie Inc (NYSE:ABBV)’s Major holders
VANGUARD GROUP INC is the top institutional holder at ABBV for having 170.66 million shares of worth $29.27 billion. And as of 2024-06-30, it was holding 9.6472 of the company’s outstanding shares.
The second largest institutional holder is BLACKROCK INC., which was holding about 136.43 million shares on 2024-06-30. The number of shares represents firm’s hold over 7.7124 of outstanding shares, having a total worth of $23.4 billion.
On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and VANGUARD INDEX FUNDS-Vanguard 500 Index Fund are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024 , the former fund manager was holding 55.37 shares of worth $10.1 billion or 3.13% of the total outstanding shares. The later fund manager was in possession of 47.83 shares on Dec 31, 2024 , making its stake of worth around $8.72 billion in the company or a holder of 2.71% of company’s stock.
